An investigation of the von Willebrand factor genotype in UK patients diagnosed to have type 1 von Willebrand disease

Summary

Forty families diagnosed by UK centres to have type 1 VWD were recruited. Following review, six families were re-diagnosed to have type 2 VWD, one to have a platelet storage pool disorder, and one family was determined to be unaffected. Direct DNA sequencing of the promoter region and all exons and intronic boundaries of the VWF gene identified six mutations likely to be causative of VWD in index cases of nine of the 32 (28%) confirmed type 1 VWD families. These included R1205H (3614G>A) VWD Vicenza, P1648fsX45 (4944delT), D141G (422A>G) and three splice site mutations: 3108+5G>A, 7437+1G>A and 3379+1G>A. The Y1584C (4751A>G) polymorphism was present in eight additional families. No significant VWF gene mutation or polymorphism was identified in 15 of the32 type 1VWD index cases (47%). Haplotype studies were performed using a panel of VWF polymorphisms to investigate the segregation in families of VWD phenotype with the VWF gene. In 13 of the 32 families it was likely that VWD segregated with the VWF gene. In eight families (25%) VWD clearly did not segregate with the VWF gene. We suggest that mutation screening of the VWF gene has limited general utility in genetic diagnostic and family studies in type 1 VWD. If genetic studies are performed, the incomplete penetrance and variable expressivity of type 1 VWD must be taken into account. Unless linkage of VWD phenotype with the VWF gene can be clearly demonstrated, the results of any genetic family studies should be interpreted with caution.

Keywords

Type 1VWD, VWF gene mutations - inherited bleeding disorders - molecular pathogenesis

• References

• 1 Rodeghiero F. von Willebrand disease: still an intriguing disorder in the era of molecular medicine. Haemophilia 2002; 08: 292-300.
• 2 Sadler JE. A revised classification of von Willebrand disease. For the Subcommittee on von Willebrand factor of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 1994; 71: 520-5.
• 3 Rodeghiero F, Castaman G, Dini E. Epidemiological investigation of the prevalence of von Willebrand’s disease. Blood 1987; 69: 454-9.
• 4 Werner EJ, Broxson EH, Tucker EL. et al. Prevalence of von Willebrand disease in children: A multiethnic study. J Pediatr 1993; 123: 893-8.
• 5 Nichols WC, Ginsburg D. Reviews in molecular medicine: von Willebrand disease. Medicine 1997; 76: 1-20.
• 6 Miller CH, Graham JB, Goldin LR. et al. Genetics of classic von Willebrand’s disease. I. Phenotypic variation within families. Blood 1979; 54: 117-45.
• 7 Castaman G, Eikenboom JCJ, Bertina RM. et al. Inconsistency of association between type 1 von Willebrand disease phenotype and genotype in families identified in an epidemiological investigation. Thromb Haemost 1999; 82: 1065-70.
• 8 Casana P, Martinez F, Haya S. et al. Significant linkage and non-linkage of type 1 von Willebrand disease to the von Willebrand factor gene. Br J Haematol 2001; 115: 692-700.
• 9 Lanke E, Johansson AM, Hallden C. et al. Genetic analysis of 31 Swedish type 1 von Willebrand disease families reveals incomplete linkage to the von Willebrand factor gene and a high frequency ofa certain disease haplotype. J Thromb Haemost 2005; 03: 2656-63.
• 10 Eikenboom J, van Marion V, Putter H. et al. Linkage analysis in families diagnosed with type 1 von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 VWD. J Thromb Haemost 2006; 04: 774-82.
• 11 James PD, Paterson AD, Notley C. et al. Genetic linkage and association analysis in type 1 von Willebrand disease: results from the Canadian Type 1 VWD Study. J Thromb Haemost 2006; 04: 783-92.
• 12 Sadler JE, Rodeghiero F. on behalf of the ISTHSS Subcommittee on von Willebrand Factor. Provisional criteria for the diagnosis of VWD type 1. J Thromb Haemost 2005; 03: 775-7.
• 13 Sadler JE. Von Willebrand disease type 1: a diagnosis in search of a disease. Blood 2003; 101: 2089-93.
• 14 Sadler JE. Slippery criteria for von Willebrand disease type 1. J Thromb Haemost 2004; 02: 1720-3.
• 15 Levy G, Ginsburg D. Getting at the variable expressivity of von Willebrand disease. Thromb Haemost 2001; 86: 144-8.
• 16 De Lange M, de Geus EJ, Kluft C. et al. Genetic influences on fibrinogen, tissue plasminogen activatorantigen and von Willebrand factor in males and females. Thromb Haemost 2006; 95: 414-9.
• 17 Orstavik KH, Magnus P, Reisner H. et al. Factor VIII and factor IX in a twin population. Evidence for a major effect of ABO locus on factor VIII level. Am J Hum Genet 1985; 37: 89-101.
• 18 Gill JC, Endres-Brooks J, Bauer PJ. et al. The effect of ABO blood group on the diagnosis of von Willebrand disease. Blood 1987; 69: 1691-5.
• 19 Keeney S, Cumming AM. The molecular biology of von Willebrand disease. Clin Lab Haem 2001; 23: 209-30.
• 20 Laffan M, Brown SA, Collins PW. et al. The diagnosis of von Willebrand disease: a guideline from the UK Haemophilia Centre Doctors’ Organisation. Haemophilia 2004; 10: 199-217.
• 21 Federici AB, Canciani MT, Forza I. et al. Ristocetin cofactor and collagen binding activities normalized to antigen levels for a rapid diagnosis of type 2 von Willebrand disease. Single center comparison of four different assays. Thromb Haemost 2000; 84: 1127-8.
• 22 Enayat MS, Hill FGH. Analysis of the complexity of the multimeric structure of factor VIII-related antigen/von Willebrand protein using a modified electrophoretic technique. J Clin Pathol 1983; 36: 915-9.
• 23 Mancuso DJ, Tuley EA, Westfield LA. et al. Structure of the gene for human von Willebrand factor. J Biol Chem 1989; 264: 19514-27.
• 24 Strauss EC, Kobori JA, Siu G. et al. Specificprimer-directed DNA sequencing. Anal Biochem 1986; 154: 353-60.
• 25 Bonfield JK, Rada C, Staden R. Automated detection of point mutations using fluorescent sequence trace subtraction. Nucleic Acids Res 1998; 26: 3404-9.
• 26 Hilbert L, Gaucher C, Mazurier C. Identification of two mutations (Arg611Cys and Arg611His) in the A1 loop of von Willebrand factor (vWF) responsible for type 2 von Willebrand disease with decreased plateletdependent function of vWF. Blood 1995; 86: 1010-8.
• 27 Castaman G, Eikenboom JCJ, Rodeghiero F. et al. A novel candidate mutation (Arg611→His) in type I “platelet discordant” von Willebrand’s disease with desmopressin-induced thrombocytopenia. Br J Haematol 1995; 89: 656-8.
• 28 Castaman G, Rodeghiero F, Mannucci PM. The elusive pathogenesis of von Willebrand disease Vicenza. Blood 2002; 99: 4243-4.
• 29 Castaman G, Missiaglia E, Federici AB. et al. An additional unique candidate mutation (G2470A; M740I) in the original families with von Willebrand disease type 2M Vicenza and the G3864A (R1205H) mutation. Thromb Haemost 2000; 84: 350-1.
• 30 Schneppenheim R, Federici AB, Budde U. et al. Von Willebrand disease type 2M “Vicenza” in Italian and German patients: identification of the first candidate mutation (G3864A; R1205H) in 8 families. Thromb Haemost 2000; 82: 136-40.
• 31 Baronciani L, Cozzi G, Canciani MT. et al. Molecular defects in type 3 von Willebrand disease: updated results from 40 multiethnic patients. Blood Cells Mol Dis 2003; 30: 264-70.
• 32 Bowen DJ, Collins PW, Lester W. et al. The prevalence of the cysteine1584 variant of von Willebrand factor is increased in type 1 von Willebrand disease: cosegregation with increased susceptibility to ADAMTS13 proteolysis but not clinical phenotype. Br J Haematol 2005; 128: 830-6.
• 33 Bowen DJ, Collins PW. An amino acid polymorphism in von Willebrand factor correlates with increased susceptibility to proteolysis by ADAMTS13. Blood 2004; 103: 941-7.
• 34 Bowen DJ. An influence of ABO blood group on the rate of proteolysis of von Willebrand factor by ADAMTS13. J Thromb Haemost 2003; 01: 33-40.
• 35 O’Brien LA, James PD, Othman M. et al. Founder von Willebrand factor haplotype associated with type 1 von Willebrand disease. Blood 2003; 102: 549-57.
• 36 Hilbert L, Jorieux S, Proulle V. et al. Two novel mutations, Q1053H and C1060R, located in the D3 domain of von Willebrand factor, are responsible for decreased FVIII-binding capacity. Br J Haematol 2003; 120: 627-32.
• 37 Berber E, James PD, Leggo J. et al. Effect of the R924Q von Willebrand factor substitution on the expression of the von Willebrand disease phenotype. Blood. 2003 102. Abstract 307.
• 38 Padgett RA, Grabowski PJ, Konarska MM. et al. Splicing of messenger RNA precursors. Annu Rev Biochem 1986; 55: 1119-50.
• 39 Bódo I, Katsumi A, Tuley EA. et al. Type 1 von Willebrand disease mutation Cys1149Arg causes intracellular retention and degradation of heterodimers: a possible general mechanism for dominant mutations of oligomeric proteins. Blood 2001; 98: 2973-9.
• 40 James PD, Notley C, Hegadorn C. et al. The mutational spectrum of type 1 von Willebrand disease: results from a Canadian cohort study. Blood first edition paper, prepublished online. August 10 2006 doi:10.1182/blood-2006-05-021105.
• 41 Keightley AM, Lam YM, Brady JN. et al. Variation at the von Willebrand factor (vWF) gene locus is associated with plasma vWF:Ag levels: identification of three novel single nucleotide polymorphisms in the vWF gene promoter. Blood 1999; 93: 4277-83.
• 42 Johansson AM, Säll T, Lethagen S. et al. The haplotype structure of the von Willebrand factor (VWF) gene promoter indicates balancing selection. J Thromb Haemost. 2005 03. (Suppl 1): Abstract P1466.
• 43 Kunicki TJ, Federici AB, Salomon DR. et al. An association of candidate gene haplotypes and bleeding severity in von Willebrand disease (VWD) type 1 pedigrees. Blood 2004; 140: 2359-67.
• 44 Di Paola J, Federici AB, Mannucci PM. et al. Low platelet a2ß1 levels in type 1 von Willebrand disease correlate with impaired platelet function in a high shear stress system. Blood 1999; 93: 3578-82.